Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eyepoint Inc (EYPT)

Eyepoint Inc (EYPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,319,625
  • Shares Outstanding, K 82,787
  • Annual Sales, $ 43,270 K
  • Annual Income, $ -130,870 K
  • EBIT $ -218 M
  • EBITDA $ -223 M
  • 60-Month Beta 1.63
  • Price/Sales 25.83
  • Price/Cash Flow N/A
  • Price/Book 6.71

Options Overview Details

View History
  • Implied Volatility 92.14% (-6.38%)
  • Historical Volatility 65.65%
  • IV Percentile 59%
  • IV Rank 27.44%
  • IV High 195.01% on 04/08/25
  • IV Low 53.23% on 07/30/25
  • Expected Move (DTE 3) 3.02 (18.93%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 101
  • Volume Avg (30-Day) 197
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 15,104
  • Open Int (30-Day) 14,416
  • Expected Range 12.92 to 18.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.78
  • Number of Estimates 3
  • High Estimate -0.71
  • Low Estimate -0.85
  • Prior Year -0.64
  • Growth Rate Est. (year over year) -21.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.35 +3.84%
on 01/12/26
19.00 -16.11%
on 12/22/25
-0.05 (-0.31%)
since 12/12/25
3-Month
9.65 +65.18%
on 11/05/25
19.11 -16.59%
on 12/08/25
+2.37 (+17.46%)
since 10/10/25
52-Week
3.91 +307.67%
on 04/09/25
19.11 -16.59%
on 12/08/25
+7.60 (+91.13%)
since 01/10/25

Most Recent Stories

More News
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

– Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets – – Pivotal Phase 3 trials in wet AMD on track for data readout beginning...

EYPT : 15.94 (-1.79%)
The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside

These biotech bets are only for investors who can stomach volatility.

EYPT : 15.94 (-1.79%)
IRD : 2.0500 (+6.22%)
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with...

EYPT : 15.94 (-1.79%)
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious...

EYPT : 15.94 (-1.79%)
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYUâ„¢ in Wet Age-Related Macular Degeneration

– No changes in protocol recommended for LUGANO and LUCIA clinical trials – – Masked safety data continues to show no safety signals, consistent with previous clinical trials for DURAVYU –...

EYPT : 15.94 (-1.79%)
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients...

EYPT : 15.94 (-1.79%)
EyePoint Pharmaceuticals: Q3 Earnings Snapshot

EyePoint Pharmaceuticals: Q3 Earnings Snapshot

EYPT : 15.94 (-1.79%)
EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments

– Phase 3 LUGANO and LUCIA clinical trials for DURAVYU ™ in wet AMD fully enrolled and on track for data readout beginning in mid-2026 – – Announced initiation of pivotal Phase 3 DME...

EYPT : 15.94 (-1.79%)
EyePoint Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...

EYPT : 15.94 (-1.79%)
EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025

WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...

EYPT : 15.94 (-1.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

EYEPOINT INC is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. EYEPOINT INC, formerly known as EyePoint Pharmaceuticals Inc., is based in WATERTOWN, Mass.

See More

Key Turning Points

3rd Resistance Point 17.48
2nd Resistance Point 16.93
1st Resistance Point 16.44
Last Price 15.94
1st Support Level 15.40
2nd Support Level 14.85
3rd Support Level 14.36

See More

52-Week High 19.11
Last Price 15.94
Fibonacci 61.8% 13.30
Fibonacci 50% 11.51
Fibonacci 38.2% 9.72
52-Week Low 3.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar